INTRODUCTION
Genetic pro®ling-based diagnosis promises to re®ne (1) and potentially revolutionize (2) the existing cancer staging system and the management of early disease. Array-based comparative genomic hybridization (array-CGH) offers global views of cancer genomes by detecting ampli®cation or deletion of cancer genes (3±10), whereas techniques like real-time PCR (11) can be used for validation and quanti®-cation of the identi®ed genomic changes.
However, such multiplexed analysis of genetic changes in tumors requires`micrograms' of pure tumor DNA (12, 13) . Routine tumor biopsies often consist of heterogeneous mixtures of stromal cells plus tumor cells with a wide range of genetic pro®les (14) . Techniques such as ®ne needle aspiration and laser capture microdissection (LCM), allow for removal of minute amounts of fresh or archived tumor tissue (14) , thereby isolating homogeneous populations of normal or tumor cells (15±17). DNA extracted from such a small number of cells has to be ampli®ed to provide suf®cient material for microarray screening. Whole genome ampli®cation may be carried out via conventional PCR. In fact, PCR may amplify whole genomic DNA from as little as a single cell (13, 18) . However, the exponential mode of DNA ampli®cation, the concentration-dependent PCR saturation and the lack of reproducibility due to stray impurities are notorious for the introduction of bias (11) . Consequently, different quantitative relationships between two genes are usually observed before and after PCR ampli®cation. Whole genome ampli®cation methods other than PCR have been described [reviewed in (19) ], including the promising multiple displacement ampli®cation (MDA) (20) . MDA operates on long DNA templates and produces linearly ampli®ed genomic DNA when starting from intact genomes obtained from cell cultures or fresh tissue. However, the ampli®cation ef®ciency of MDA is diminished as the molecular weight of the starting material decreases, which is problematic for ampli®cation of formalin®xed archival DNA or low molecular weight DNA from deteriorated forensic samples (21) .
Here we describe a PCR-based approach to amplify genomic DNA of two different origins, one from cancer cells and another from normal cells. This method does not require intact, long genomic DNA as starting material and allows removal of ampli®cation bias caused by PCR saturation and impurities down to the single gene level. Genomic DNA is ®rst digested with a 4 bp cutting restriction nuclease. Following ligation of composite linkers to the two DNAs, the samples are mixed and PCR ampli®ed in a single tube (Fig. 1) . The single tube ampli®cation of the mixed samples is aimed at eliminating PCR biases related to PCR saturation and impurities, since the polymerase cannot distinguish among alleles originated from normal or cancer genomes. A nested, genome-speci®c primer is subsequently used in a low-yield, second PCR to re-separate DNA fragments from the two original genomes on the basis of nucleotide`tags' incorporated in the composite linkers. We previously demonstrated the utility of this balanced-PCR approach for the unbiased ampli®cation of cDNA prior to gene expression microarray screening (22) . The increased complexity of genomic DNA relative to cDNA required modi®cation of our original approach. We describe an improved single tube procedure that allows application of balanced-PCR to genomic DNA obtained from about 1000 cells, and we demonstrate its use for array-CGH and real-time PCR quanti®cation of gene copy numbers from normal and breast cancer cells and for modestly degraded DNA obtained from paraf®n-embedded tissue.
MATERIALS AND METHODS

Cell lines and genomic DNA
Breast cancer cells BT-474 and human mammary epithelial cells (HMEC) were obtained from the American Type Culture Collection (Manassas, VA) and from Cambrex (Rockland, ME), respectively, and were cultured as per the companies' recommendations. Total genomic DNA was then isolated from cultured cells using the QIAampÔ DNA Mini Kit (Qiagen, Valencia, CA). Genomic DNA from paraf®n-embedded tissue was extracted using the Qiagen EZ1Ô paraf®n kit.
Single tube procedure for balanced-PCR
The linkers and primers used for the balanced-PCR protocol in Figure 1 were synthesized by Oligos Etc. Inc. (Wilsonville, OR) and are depicted in Table 1 . A single tube procedure was used for digestion and ligation of BT474 (`target') and HMEC (`control') genomic DNA with genome-speci®c linkers. Genomic DNA (5 ng) was digested in a 5 ml total reaction volume using restriction enzyme NlaIII (10 units/ml stock, 37°C, 2 h; New England Biolabs, Beverly, MA) in 1Q buffer (50 mM Tris±HCl, pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 1 mM ATP, 25 mg/ml BSA). NlaIII was subsequently inactivated by incubation at 70°C for 1 h. Composite linkers LN1 and LN2 (0.3 ml from a 2.8 mg/ml stock in a 10 ml reaction volume) were then ligated to DNA from BT474 (target) and HMEC (control) cells, respectively, using T4 DNA ligase (New England Biolabs) at room temperature for 1 h. After inactivation of ligase at 65°C for 40 min, the linker-ligated target and control DNAs were mixed.
The DNA mixture was PCR-ampli®ed using the common oligonucleotide P1 in a Tech-GeneÔ PCR thermocycler (Techne, Princeton, NJ) with Advantage 2 DNA polymerase (BD Biosciences, Palo Alto, CA). Thermocycling conditions were: 8 min at 72°C; 1 min at 95°C; 20 Q (30 s at 95°C and 60 s at 72°C); 5 min at 72°C. Following thorough DNA puri®cation with a QIAquickÔ PCR Puri®cation Kit to remove unincorporated primer P1, PCR products were quanti®ed using a PicoGreen assay (Molecular Probes, Eugene, OR). To re-separate PCR products originating from target and control genomes, a low-yield PCR was carried out using primers P2a (BT474 target genome) or P2b (HMEC control genome) which contain two-nucleotide`tags' at their ends that distinguish the two genomes. In each reaction, 1±2 ng from the ®rst PCR product was ampli®ed using the Titanium PCR kit (BD Biosciences) with the following thermocycling conditions: 1 min at 95°C; 10 Q (30 s at 95°C and 60 s at 72°C); 5 min at 72°C. Alternatively, instead of BT474 DNA, the target DNA used for balanced-PCR ampli®cation was DNA (10 ng) extracted from paraf®n-embedded tissue.
The ef®ciency of NlaIII was routinely monitored during balanced-PCR, as previously described (22), and we have found that restriction digestion is >95% complete. The ligation ef®ciency was also monitored; however, this is somewhat less critical, since every sample is normalized to internal housekeeping genes (GAPDH) and therefore a reduced ligation ef®ciency should affect both the housekeeping gene ampli®-cation and the particular gene tested.
Multiple displacement ampli®cation (MDA)
MDA was performed for target (BT474) and control (HMEC) genomic DNAs using the Repli-gÔ whole genome ampli®cation kit (Molecular Staging, New Haven, CT) according to kit instructions. Brie¯y, 5 ng of either BT474 or HMEC genomic DNA was brought to a ®nal volume of 2.5 ml with sterile, distilled water. A reaction master mix was prepared by adding 12.5 ml of 4Q mix, 0.5 ml of DNA polymerase mix and 34.5 ml of sterile, distilled water. The reaction master mix was added to the DNA, and samples were incubated at 30°C for 16 h, following which the enzyme was heat-denatured at 65°C for 3 min. The concentration of ampli®ed samples was determined using a PicoGreen DNA quanti®cation assay (Molecular Probes). Alternatively, the target DNA used for MDA ampli®cation was DNA (50 ng) extracted from paraf®n-embedded tissue.
Quantitation using real-time (TaqMan) PCR
Real-time PCR, TaqMan (23) assays, were performed to determine the relative copy number of speci®c genes in target DNA (BT474 or DNA from paraf®n-embedded tissue) relative to control DNA (HMEC) for unampli®ed genomic DNA, balanced-PCR ampli®ed DNA and MDA-ampli®ed DNA. TaqMan assays were performed using AmpliTaq GoldÔ (Applied Biosystems, Foster City, CA) in an ABI Prism 7900HT detection system. Some experiments were also performed using Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA) in a Smart-CyclerÔ (Cepheid, Sunnyvale, CA). Primers and probes for exonic regions of 13 genes (Table 1) were designed using Oligo software (v. 6.65, Molecular Biology Insights Inc., West Cascade, CO) and PrimerExpress software (Applied Biosciences, ABI, Foster City, CA) and were obtained from Bioresearch Technologies (Novato, CA). Three independent triplicates of quantitative PCR experiments were performed for each gene to generate an average relative copy number and standard deviation. For each triplicate, 3 ng of DNA was added to a ®nal volume of 70 ml with a ®nal concentration of 1Q ABI TaqMan master mixÔ, 4 mM each primer and 2 mM probe. This reaction mix was split into three different 20 ml PCRs and thermo-cycled. The cycling program was one cycle at 50°C for 2 min, one cycle at 95°C for 10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min. The relative genomic copy number was calculated using the comparative threshold (Ct) method (11) . Brie¯y, the threshold cycle (C T ) for each gene was determined using the thermocycler software and the average of three independent Cts/DNA was calculated. The copy number of the target gene normalized to an endogenous reference and relative to calibrator is given by the formula 2 ±DDCT . GAPDH was used as an endogenous reference, and DC T was calculated by subtracting the average GAPDH C T from the average C T of the gene of interest. A variety of calibrator DNAs were used to calculate DDC T (DC T DNA of interest ± DC T calibrator DNA ). For BT474 or paraf®n samples ampli®ed via balanced-PCR, coampli®ed HMEC DNA was used as a calibrator. For unampli®ed BT-474 or unampli®ed paraf®n DNA, unampli®ed HMEC was used as calibrator. For MDA-ampli®ed BT474 or paraf®n DNA, MDA-ampli®ed HMEC was used as a calibrator.
Array-CGH using cDNA microarrays
Array-based comparative genomic hybridization (Array-CGH) was performed on Agilent Human 1 cDNA microarrays using NlaIII digested DNA from unampli®ed BT474 and HMEC genomic DNA, balanced-PCR-ampli®ed DNA, and MDA-ampli®ed DNA. Alternatively, BT474 DNA was replaced with paraf®n-extracted DNA. For each labeling reaction, 2 mg of digested DNA (ampli®ed or unampli®ed) was used. Each sample pair was dye-swap labeled for hybridization. Brie¯y, DNA samples (2 mg) were denatured in the presence of Random Primer and Reaction Buffer (Invitrogen BioPrime Labeling Kit) at 98°C for 5 min, and then cooled to 2°C for 5 min. The denatured sample was incubated with Klenow fragment, dNTP mix (2.0 mM dATP dGTP dTTP, 1.0 mM dCTP in 10 mM Tris pH 8.0, 1 mM EDTA) and Cy3 or Cy5 dCTP nucleotides (1 mM; Perkin Elmer) for 2 h at 37°C. Reactions were terminated using EDTA (0.5 M, pH 8.0) Cy3 and Cy5 reaction pairs (labeled pair = Cy5-sample:Cy3-reference; reversed labeled pair = Cy3-sample:Cy5-reference) were pooled, precipitated and resuspended in 18.5 ml of 0.514% SDS. Samples were mixed with blocking solution concentrated from 50 ml of human Cot-1 DNA (1 mg/ml; Gibco), 20 ml of yeast tRNA (5 mg/ml; Gibco) and 4 ml (dA)± poly(dT) (5 mg/ml; Sigma). SSC was added to a ®nal concentration of 3.4Q and 2.5 ml of Deposition Control Target (Operon) was added to a ®nal volume of 30 ml. For hybridization, samples are denatured at 98°C for 2 min, then cooled at 37°C for 30 min under light-protection with foil. Labeled reactions in a volume of 27.5 ml were pipetted onto Agilent Human 1 cDNA arrays. Hybridization was carried out for 18±20 h in a 65°C water bath. After hybridization was complete, arrays were washed in 2Q SSC±SDS [100 ml of 20Q SSC, 0.03% SDS (10%) (v/v)] at 65°C for 5 min, followed by additional 5 min wash steps in 1Q SSC, then 0.2Q SSC, each at room temperature. After drying, hybridized arrays were scanned on an Axon scanner and spot ®nding and agging were accomplished using GenePix software. Custom tools developed at the Belfer Center for Cancer Genomics (C. Brennan and L. Chin, manuscript in preparation) including cDNA-to-chromosome mapping, exclusion of non-reporters, ratio calculation, normalization and visualization were used to compile the CGH pro®les from these array data points.
RESULTS
Single tube balanced-PCR protocol
We explored the application of balanced-PCR to the ampli®cation of whole genomic DNA and the detection of changes in gene copy number via array-CGH and real-time PCR. The complex nature of genomic DNA required modi®cation of the originally reported protocol developed for gene expression pro®ling (22) , and a single tube approach was employed for DNA digestion and linker ligation. The single tube approach results to higher reproducibility when working with small amounts of DNA, since it avoids an intermediate puri®cation step and is convenient to perform. NlaIII endonuclease is used to digest DNA (Fig. 1) to generate fragments that contain recessed 5¢ ends and 3¢ overhangs, which can be linker ligated without addition of an adaptor. This design feature allows the use of a single tube process without puri®cation, because PCR artifacts are known to occur in the presence of excessive adaptors. The linker length has been reduced to 28 bp from the original 44 bp, since shorter linkers avoid PCR suppression effects by reducing hairpin formation (24) . Distinction between the genome-speci®c primers P2a and P2b is based on two nucleotide`tags' on their 3¢ end (5¢-AG-3¢ versus 5¢-GA-3¢; Fig. 1 ). The two base mismatch at the 3¢ end of the primers P2a and P2b prevents P2a from amplifying sequences from the LN1-ligated (target) genome and vice versa, while it retains similarity in the remaining part of the primer sequence. The lack of cross-talk between the genome-speci®c primers is Figure 2 , where target and control genomic DNA were ampli®ed as per the protocol in Figure 1 and then separated using primers P2a and P2b (lanes 1 and 4, respectively). The products of lanes 1 and 4 were subsequently ampli®ed for 10 additional cycles using primers P2a and P2b (lanes 2 and 3, respectively), i.e. the`wrong' primers. The lack of product in lanes 2 and 3 demonstrates the speci®city of the two primers, P2a and P2b, for their respective genomes.
Reproducibility of array-CGH pro®ling
To evaluate the reproducibility of the overall procedurebalanced-PCR ampli®cation plus array-CGH screening, the experiment was repeated two independent times starting with 5 ng each of HMEC and BT474 DNA. The results from replicate experiments were compared to derive an estimate of the combined errors due to random variations in the ef®ciency of digestion, ligation and balanced-PCR ampli®cation, and signal differences/defects of individual cDNA microarrays. A generally good agreement was demonstrated between replicate experiments as depicted for chromosomes 17 and 20 in Figure 3 . Concordance between the two sets of data was R 2 = 0.51, which increased substantially if nearest neighbor averaging was applied to the data (R 2 = 0.71, 0.79 and 0.87 for averaging signals by two, ®ve and 12 nearest neighbors along each chromosome). Whether signals from neighbor chromosomal sites were averaged or not, genomic loci with relatively high gene-dosage alterations could still be detected with high reproducibility among different experiments (vide infra). These results indicate that the array signals tend to¯uctuate randomly and signal variability is similar to the previously reported levels for replicate array-CGH experiments (21) . To balance the need of improving signal reproducibility and preserving the highest resolution that microarrays can offer, a two-nearest neighbor averaging was applied in array-CGH data analysis. By following this approach, it was estimated that the average distance between successive chromosomal regions in the resulting data sets is~300 kb.
Genomic copy number screening (array-CGH) of breast cancer cells
Gene copy number ratios in BT474 (target) and HMEC (control) genomic DNAs were compared to each other prior to and after balanced-PCR ampli®cation. First, 5 mg (~1 000 000 cells) of unampli®ed BT474 and HMEC genomic DNA was directly labeled and hybridized to cDNA microarrays and the resulting array-CGH pro®les of copy number ratios are shown in Figure 4 . The reported differences between the well studied BT474 breast cancer cell line and normal human female (HMEC) were reproduced in this comparison, including the multiple ampli®cation regions in chromosomes 17q and 20q, the ampli®cations in chromosomes 9, 11 and 14 and the deletions in chromosome 10 previously observed by conventional CGH (4,25) and array-CGH (5,26). Next, 5 ng (~1000 cells) of genomic DNA from BT474 and HMEC cells was ampli®ed using balanced-PCR and analyzed for comparative gene dosage via array-CGH (Fig. 5) . The results demonstrate an overall pattern of gene ampli®cations and deletions resembling that of unampli®ed DNA (shaded areas in Fig. 5 ). The comparison was also performed using MDAampli®ed material and the concordance among balanced-PCR ampli®ed, MDA-ampli®ed and unampli®ed samples was further analyzed for chromosomes 17 and 20 where marked gene dosage changes were observed. Figure 6 depicts twonearest neighbor-smoothed gene dosage data for target (BT474) versus control female (HMEC) DNA for chromosomes 17 and 20 using these two ampli®cation methods. It is evident that both balanced-PCR and MDA are capable of reproducing the major genetic changes occurring in the genome of the cancerous BT474 cells. For chromosome 17, array-CGH data demonstrated a correlation coef®cient R 2 = 0.67 (two-nearest neighbor averaging) and R 2 =0.90 (12-nearest neighbor averaging) when comparing fold change using balanced-PCR-ampli®ed DNA with unampli®ed DNA. The same analysis conducted using MDA-ampli®ed DNA (Fig. 6 ) generated R 2 = 0.77 (two-nearest neighbor averaging) and R 2 = 0.88 (12-nearest neighbor averaging). Comparable levels of concordance were also derived by analysis on chromosome 20. The concordance levels for balanced-PCR and MDA are similar to the concordance observed in the replicate-reproducibility studies depicted in Figure 3 . Since replicate balanced-PCR experiments generated similar levels of concordance to that observed when ampli®ed and unampli®ed samples are compared, it was concluded that the two ampli®cation methods, balanced-PCR and MDA, did not introduce substantial bias during DNA ampli®cation (i.e. ampli®cation bias < array-CGH bias). Many of the genes included in the ampli®ed regions of chromosomes 17 and 20 have a well established association with cancer. For example, RAE 1, PCK, HOX and HER2 are highly ampli®ed in BT474 cells and are a prognostic marker for breast tumors (25, 27, 28) . Ampli®cation in these genes was clearly depicted among all replicate experiments in the array-CGH data for both of the ampli®cation methodologies tested.
Real-time PCR measurement of gene copy number in target versus control cells
For many research and diagnostic applications, the array-CGH-identi®ed gene copy number changes need to be further veri®ed via real-time PCR. To evaluate the two ampli®cation methodologies, balanced-PCR and MDA, on a gene-by-gene level, we chose genes that are located in chromosomal regions where gene ampli®cation was observed in array-CGH pro®l-ing: HER2, PCK, RAE and HOX. Genes were also selected Figure 2 . Evaluation of the speci®city of primers P2a and P2b for amplifying target and control genomes ligated to LN1 and LN2, respectively. The protocol of Figure 1 was applied to co-amplify and, subsequently, to re-separate the two genomes. Lane 1, P2a-ampli®ed genome; lane 4, P2b-ampli®ed genome; lanes 2 and 3, the products depicted in lanes 1 and 4 were further ampli®ed for 10 cycles using P2b and P2a primers, respectively.
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Nucleic from regions that do not indicate ampli®cation: E2F, TOP1, RAN, Tfr, HBEGF, IL9R, TBP and CYC. TaqMan assayderived copy number ratios (`fold change' between BT474 and HMEC DNA) were then compared for ampli®ed versus unampli®ed samples (Fig. 7) . Genetic ampli®cation, or lack of ampli®cation, was correctly indicated for both, unampli®ed and balanced PCR-ampli®ed DNA, for 11 of the 12 genes examined. One gene (HOX) was classi®ed as a false negative since no ampli®cation would have been demonstrated following a blind screen of balanced-PCR ampli®ed samples. It is noteworthy that the array-CGH data for the HOX gene demonstrated good agreement between balanced-PCR and unampli®ed samples (fold change of 6.1 and 8, respectively). These data seem to suggest that the reason for the false negative in HOX may lie with the speci®c use of balanced-PCR ampli®ed DNA in TaqMan assays. For example, since DNA ampli®ed via balanced-PCR is NlaIII digested, potential NlaIII polymorphisms could affect TaqMan primer/probe binding sites in the target or the control DNA.
In a real-time PCR screen similar to that conducted for balanced-PCR, MDA ampli®cation also indicated generally good agreement of genetic differences observed for unampli®ed DNA for 11 of the 12 genes examined (Fig. 7) . One gene (TOP1) was classi®ed as a false positive, since a blind screen would have demonstrated signi®cant (6-fold) gene ampli®ca-tion for MDA-ampli®ed samples, but not for unampli®ed or balanced-PCR ampli®ed DNA.
Screening of DNA from formalin-®xed, paraf®n-embedded tissue DNA obtained from paraf®n-embedded tissue (glioblastoma, <5 years years since formalin ®xation) was either used directly (unampli®ed) for array-CGH or real-time PCR screening, or was ®rst ampli®ed via balanced-PCR or MDA and subsequently screened using HMEC DNA as the co-ampli®ed control. DNA obtained from formalin-®xed tissue was modestly degraded (gel electrophoresis pro®le depicted in Fig. 8A ). Following ampli®cation via balanced-PCR the sample was screened via array-CGH and real-time PCR. The array-CGH pro®ling successfully revealed the main features obtained from direct screening of unampli®ed samples ( Fig. 8B and C) . In Frame B, array-CGH pro®les from all 23 chromosomes are depicted and regions of ampli®cation in chromosome 4 are indicated. In Figure 8C the chromosomal region from chromosome 4¯anking the ampli®ed region of interest (~7 Mb long) is shown. To examine reproducibility, the experiment was conducted in duplicate and both array-CGH pro®les demonstrated the same chromosome 4 feature (Fig. 8C) . Similarly, when examined via Taqman real-time PCR, samples ampli®ed via balanced-PCR demonstrated concordance with unampli®ed DNA for eight out of nine genes examined (Fig. 8D) . In contrast, MDA universally generated low or insigni®cant ampli®cation of formalin-®xed DNA and array-CGH/real-time PCR screening failed to produce substantial signals. These data indicate that, for formalin-®xed samples of modest degradation, such as the one depicted in Figure 8A , balanced-PCR can be successfully used for array-CGH and real-time PCR evaluation.
DISCUSSION
The ability of balanced-PCR to overcome problems associated with ampli®cation of modestly degraded DNA may be associated with the initial digestion of DNA followed by adaptor ligation, which generates a substantial number of DNA fragments lacking formalin-associated DNA damage, and which can then be ampli®ed. Evidence exists that ampli®cation performed in this manner is not substantially inhibited by formalin-induced DNA damage. Klein and colleagues described SCOMP (13, 29) , which utilizes DNA digestion and adaptor ligation to perform whole genome PCR ampli®cation and comparative genomic hybridization when starting from a single cell. Because SCOMP utilizes digested, low molecular weight DNA as starting material, it was capable of ef®cient ampli®cation of DNA from formalin-®xed samples and was found to be superior to DOP-PCR (29) . However, the issue of ampli®cation bias using SCOMP was not adequately addressed since the method was not validated at high resolution, i.e. via array-CGH or on a gene-by-gene basis. Due to the aforementioned PCR shortcomings, SCOMP is expected to cause substantial ampli®cation bias. In our hands, SCOMP produced skewed results on a gene-by-gene basis (data not shown).
Therefore, in this work we adapted balanced-PCR, which removes biases associated with PCR saturation and impurities (22) , to the ampli®cation of genomic DNA followed by array-CGH or real-time PCR quanti®cation of gene copy number. We utilized 5 ng of genomic DNA, an equivalent tõ 1000 cells, which is similar to the amount of DNA usually obtained from LCM microdissection (~5±20 ng). Upon high-resolution examination of gene copy numbers using array-CGH, balanced-PCR demonstrated an unbiased representation of the true allelic differences between the breast cancer cell line BT474 and normal mammary epithelial cells, indicating that the method can be applied for the genome-wide examination of genetic differences among cell lines or minute tumor biopsies and normal tissues. A parallel examination using real-time PCR demonstrated that the resulting gene copy differences between tumor and normal breast genomes are generally larger than array-CGH data, both for ampli®ed and unampli®ed samples. This`dynamic range compression' is commonly observed with array-CGH (21) and indicates the importance of performing TaqMan-based veri®cation of array-detected gene-dosage changes. To further evaluate the performance of balanced-PCR we compared it with MDA. MDA is currently considered the method of choice for certain genomics applications due to the low incidence of non-speci®c ampli®cation artifacts or bias among alleles and for enabling genome-wide genotyping of small samples (30±32). In a direct comparison of balanced-PCR with MDA, when using fresh DNA samples, both methods demonstrated an approximately equivalent performance and resulted in a satisfactory ampli®cation of previously described, tumor-related differences among the two cell lines. MDA ampli®cation results in ampli®ed DNA of higher molecular weight, thus it may be more appropriate for situations where a representation of most genomic regions is required, or where undigested DNA is required for subsequent analysis. Since balanced-PCR cannot effectively amplify large (>2 kb) fragments which may potentially exist due to the location of successive NlaIII sites in a genome, the method is expected to amplify a small fraction [a`representation' (12)] of the genome rather than the entire genome. When DNA from fresh samples is used, it may be advisable to perform both balanced-PCR and MDA ampli®cations whenever possible, since an agreement with regards to gene ampli®cation and deletion by the two methods may provide higher detection accuracy. Based on our quantitation results, the gene copy number variation for 12 On the other hand, MDA demonstrated an almost complete failure to amplify material from formalin-®xed sample of modestly degraded DNA, which balanced-PCR was capable of amplifying. Several well preserved formalin-®xed tissue samples fall in this category and therefore may be ampli®ed successfuly via balanced-PCR. The nucleotidè tags' incorporated in the primers P2a and P2b during balanced-PCR can potentially be varied to include many distinct nucleotide combinations, each amplifying a different linker LN 1 , LN 2 , LN 3 , ¼, LN N . Consequently, it should be feasible to mix N genomes simultaneously and amplify them in a PCR. Thereby, large sets of archived samples could be ampli®ed in a single, unbiased PCR ampli®cation to provide an essentially unlimited resource of ampli®ed materials. This resource may not only enable investigators who utilize different microarray platforms to perform inter-comparison studies, but also facilitate the establishment of tissue banks for clinicopathological studies in the future.
In summary, we have developed a balanced-PCR wholegenome ampli®cation methodology and shown its effective- 
